Abstract
Fingolimod is a sphingosine 1-phosphate (S1P) analogue that has antagonistic effects on S1P receptors. It creates an immunosuppressive effect by decreasing the number of circulating lymphocytes by preventing the exit of lymphocytes from lymphoid tissues. The causal link between fingolimod treatment and warts has not yet been proven. Herein, we report a case of relapsing–remitting multiple sclerosis in which multiple warts developed on the right hand over the years after the initiation of fingolimod treatment and disappeared completely after discontinuation of treatment. Conclusions: The temporal relationship between discontinuation of treatment and healing of lesions, as in our case, supports a possible causal role of fingolimod and new warts did not form while receiving ocrelizumab treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
